Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

First Posted Date
2021-09-30
Last Posted Date
2023-12-29
Lead Sponsor
Gruppo Oncologico del Nord-Ovest
Target Recruit Count
477
Registration Number
NCT05062889
Locations
🇮🇹

Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy

🇮🇹

Azienda Ospedaliera Cardinale Giovanni Panico, Tricase, Lecce, Italy

🇮🇹

Ospedale San Donato di Arezzo, Arezzo, Italy

and more 25 locations

Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

First Posted Date
2021-09-20
Last Posted Date
2024-12-05
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
17
Registration Number
NCT05049863
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

First Posted Date
2021-09-17
Last Posted Date
2021-09-17
Lead Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Target Recruit Count
153
Registration Number
NCT05047991

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

First Posted Date
2021-09-13
Last Posted Date
2022-02-10
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT05042934
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

First Posted Date
2021-09-10
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
7
Registration Number
NCT05039944
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy

First Posted Date
2021-09-02
Last Posted Date
2022-09-02
Lead Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Target Recruit Count
35
Registration Number
NCT05031975
Locations
🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, MI, Italy

SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

First Posted Date
2021-08-26
Last Posted Date
2024-10-15
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
40
Registration Number
NCT05022654
Locations
🇨🇳

Anyang Cancer Hospital of Henan Province, Anyang, Henan, China

🇨🇳

Suining Central Hospital, Suining, Sichuan, China

🇨🇳

Xuzhou Central Hospital, Xuzhou, Jiangsu, China

and more 3 locations

FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

First Posted Date
2021-08-24
Last Posted Date
2021-08-24
Lead Sponsor
West China Hospital
Target Recruit Count
69
Registration Number
NCT05018182
Locations
🇨🇳

Sichuan University West China Hospital, Chengdu, Sichuan, China

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

First Posted Date
2021-08-18
Last Posted Date
2024-07-11
Lead Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Target Recruit Count
17
Registration Number
NCT05009953
Locations
🇨🇳

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China

Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer

First Posted Date
2021-08-03
Last Posted Date
2021-08-03
Lead Sponsor
Peking University
Target Recruit Count
44
Registration Number
NCT04988191
Locations
🇨🇳

Peking University Cancer Hospital and Institute, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy